Výsledky vyhledávání - "Carnevali Daniel"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Autor: Varona, José F., Landete, Pedro, López-Martín, José A., Estrada, Vicente, Paredes, Roger, Guisado Vasco, P., Fernández de Orueta, Lucía, Torralba, Miguel, Fortún, Jesús, Vates, Roberto, Barberán, José, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemí, Porras, Lourdes, Gijón, Paloma, Monereo, Alfonso, Abad, Daniel, Zúñiga Lucas, Sonia, Solá Gurpegui, Isabel, Rodón, Jordi, Vergara-Alert, Júlia, Izquierdo-Useros, Núria, Fudio, Salvador, Pontes, María José, Rivas, Beatriz de, Girón de Velasco, Patricia, Nieto, Antonio, Gómez, Javier, Avilés, Pablo, Lubomirov, Rubin, Belgrano, Álvaro, Sopesén, Belén, White, Kris M., Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin, Thorne, Lucy G., Jolly, Claire, Towers, Greg J., Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, Enjuanes Sánchez, Luis CSIC ORCID, Fernández-Sousa, José M., Plitidepsin – COVID - 19 Study Group, Krogan, Nevan J., Jimeno, José M., García-Sastre, Adolfo, McGovern, Briana L., Rodríguez, M. Luis, Enjuanes Sánchez, Luis

Publikováno v: IRTA Pubpro. Open Digital Archive
Institut de Recerca i Tecnologia Agroalimentàries (IRTA)
Life science alliance, vol 5, iss 4
Digital.CSIC. Repositorio Institucional del CSIC
instname

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung ove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45abec692e27b27fa056ad5cddea3c0
https://ddd.uab.cat/record/252184

Zobrazit plný text záznamu

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Autor: Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely, Mi-Young Ahn, Miriam Akasbi, Javier David Altclas, Federico Ariel, Horacio Alberto Ariza, Chandrasekhar Atkar, Anselmo Bertetti, Meenakshi Bhattacharya, Maria Luisa Briones, Akshay Budhraja, Aaliya Burza, Adrian Camacho Ortiz, Roberto Caricchio, Marcelo Casas, Valeria Cevoli Recio, Won Suk Choi, Emilia Cohen, Angel Comulada-Rivera, Paul Cook, Dora Patricia Cornejo Juarez, Carnevali Daniel, Luiz Fernando Degrecci Relvas, Jose Guillermo Dominguez Cherit, Todd Ellerin, Dmitry Enikeev, Suzana Erico Tanni Minamoto, Elie Fiss, Motohiko Furuichi, Kleber Giovanni Luz, Jason D. Goldman, Omar Gonzalez, Ivan Gordeev, Thomas Gruenewald, Victor Augusto Hamamoto Sato, Eun Young Heo, Jung Yeon Heo, Maria Hermida, Yuji Hirai, David Hutchinson, Claudio Iastrebner, Octavian Ioachimescu, Manish Jain, Maria Patelli Juliani Souza Lima, Akram Khan, Andreas E. Kremer, Thomas Lawrie, Mark MacElwee, Farah Madhani-Lovely, Vinay Malhotra, Michel Fernando Martínez Resendez, James McKinnell, Patrick Milligan, Cesar Minelli, Miguel Angel Moran Rodriguez, Maria Leonor Parody, Priscila Paulin, Priscilla Pemu, Ana Carolina Procopio Carvalho, Massimo Puoti, Joshua Purow, Mayur Ramesh, Alvaro Rea Neto, Philip Robinson, Cristhieni Rodrigues, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Morton Scheinberg, Stefan Schreiber, Dario Scublinsky, Anete Sevciovic Grumach, Imad Shawa, Jesus Simon Campos, Nidhi Sofat, Christoph D. Spinner, Eduardo Sprinz, Roger Stienecker, Jose Suarez, Natsuo Tachikawa, Hasan Tahir, Brian Tiffany, Alexander Vishnevsky, Adilson Westheimer Cavalcante, Kapil Zirpe

Publikováno v: The Lancet. Respiratory Medicine

Summary Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf64edd09bbf67d7978734149d4c838a
http://europepmc.org/articles/PMC8409066